The correlation between cellular O-GlcNAcylation and sensitivity to O-GlcNAc inhibitor in colorectal cancer cells.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 09 07 2024
accepted: 02 10 2024
medline: 16 10 2024
pubmed: 16 10 2024
entrez: 16 10 2024
Statut: epublish

Résumé

The upregulation of O-GlcNAc signaling has long been implicated in the development and progression of numerous human malignancies, including colorectal cancer. In this study, we characterized eight colorectal cancer cell lines and one non-cancerous cell line for O-GlcNAc-related profiles such as the expression of OGT, OGA, and total protein O-GlcNAcylation, along with their sensitivity toward OSMI-1 (Os), an OGT inhibitor (OGTi). Indeed, Os dose-dependently suppressed the viability of all colorectal cancer cell lines tested. Among the three O-GlcNAc profiles, our results revealed that Os IC50 exhibited the strongest correlation with total protein O-GlcNAcylation (Pearson Correlation Coefficient r = -0.73), suggesting that total O-GlcNAcylation likely serves as a better predictive marker for OGTi sensitivity than OGT expression levels. Furthermore, we demonstrated that Os exhibited a synergistic relationship with regorafenib (Re). We believed that this synergism could be explained, at least in part, by the observed Re-mediated increase of cellular O-GlcNAcylation, which was counteracted by Os. Finally, we showed that the Os:Re combination suppressed the growth of NCI-H508 tumor spheroids. Overall, our findings highlighted OGTi as a potential anticancer agent that could be used in combination with other molecules to enhance the efficacy while minimizing adverse effects, and identified total cellular O-GlcNAcylation as a potential predictive marker for OGTi sensitivity.

Identifiants

pubmed: 39413067
doi: 10.1371/journal.pone.0312173
pii: PONE-D-24-28155
doi:

Substances chimiques

N-Acetylglucosaminyltransferases EC 2.4.1.-
Acetylglucosamine V956696549
Pyridines 0
regorafenib 24T2A1DOYB
Phenylurea Compounds 0
OGT protein, human EC 2.4.1.255
N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime 132489-69-1
Enzyme Inhibitors 0
Oximes 0
Phenylcarbamates 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0312173

Informations de copyright

Copyright: © 2024 Wongprayoon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Pawaris Wongprayoon (P)

Faculty of Pharmacy, Department of Biomedicine and Health Informatics, Silpakorn University, Nakhon Pathom, Thailand.
Faculty of Pharmacy, Bioactives from Natural Resources Research Collaboration for Excellence in Pharmaceutical Sciences (BNEP), Silpakorn University, Nakhon Pathom, Thailand.

Supusson Pengnam (S)

Faculty of Pharmacy, Department of Biomedicine and Health Informatics, Silpakorn University, Nakhon Pathom, Thailand.
Faculty of Pharmacy, Center of Precision Medicine Innovation and Advanced Medicinal Product Development, Silpakorn University, Nakhon Pathom, Thailand.
Faculty of Pharmacy, Green Innovations Group (PDGIG), Silpakorn University, Nakhon Pathom, Thailand.

Roongtiwa Srisuphan (R)

Faculty of Pharmacy, Bioactives from Natural Resources Research Collaboration for Excellence in Pharmaceutical Sciences (BNEP), Silpakorn University, Nakhon Pathom, Thailand.

Praneet Opanasopit (P)

Faculty of Pharmacy, Center of Precision Medicine Innovation and Advanced Medicinal Product Development, Silpakorn University, Nakhon Pathom, Thailand.
Faculty of Pharmacy, Green Innovations Group (PDGIG), Silpakorn University, Nakhon Pathom, Thailand.
Faculty of Pharmacy, Department of Industrial Pharmacy, Silpakorn University, Nakhon Pathom, Thailand.

Siwanon Jirawatnotai (S)

Faculty of Medicine Siriraj Hospital, Siriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Mahidol University, Bangkok, Thailand.
Faculty of Medicine Siriraj Hospital, Department of Pharmacology, Mahidol University, Bangkok, Thailand.
Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand.

Purin Charoensuksai (P)

Faculty of Pharmacy, Department of Biomedicine and Health Informatics, Silpakorn University, Nakhon Pathom, Thailand.
Faculty of Pharmacy, Bioactives from Natural Resources Research Collaboration for Excellence in Pharmaceutical Sciences (BNEP), Silpakorn University, Nakhon Pathom, Thailand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH